3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Investor Presentation (February 2026)
48 slides from 3b Blackbio Dx's investor presentation, Feb 6, 2026
Slide 1: Cover letter to BSI
(Formerly – Kilpest India Limited) Ref. No.P-66/2025-26/74 February 6, 2026 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agrochem
Slide 2: Investor Presentation February 2026
Since 1972 Investor Presentation February, 2026
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by 3B BlackBio Dx Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Financial Highlights – Consolidated - Q3 2025-26
Financial Highlights – Consolidated - Q3 2025-26 * 5,034.73 Q3 2024-25 Q3 2025-26 ** ** 2,539.25 2,683.98 2,244.29 1,779.61 26.19 1,349.52 15.75 Revenue from Operations PBT PAT EPS Rs. In Lakh Consolidated Q3 2024-25 Q3 2025-26 Revenue from Operations 2,539.25 5,034.73* Profit Before tax 1,779.61 2,
Slide 5: Key Highlights – Agrochemicals Division
Key Highlights – Agrochemicals Division Main Thrust Area of R&D Development of novel formulations for agriculture and public health which are less harmful and cost effective. Performance monitoring of existing products/process. Improvement in existing products/process with a customer driven ap
Slide 6: Agrochemicals - Existing Products
Agrochemicals - Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 •
Slide 7: Selected as part of Select 200 Companies
3B BlackBio has been selected as a part of “Select 200 Companies” with the global business potential at DGEMS2023 held in Delhi on 27th October 2023 presented by Forbes India & D Globalist.
Slide 8: Financial Highlights: Molecular Diagnostics (MDx) Division Q3 2025-26
Financial Highlights: Molecular Diagnostics (MDx) Division Q3 2025-26
Slide 9: Overview – MDx Division
Overview – MDx Division Founded: November 2010 | 15 years in molecular diagnostics Core Focus: Design, Development & Manufacture of Molecular Diagnostic Kits: qPCR Assays (TRUPCR ®) Lateral Flow Assays (TRURAPID ®) NGS Assays (TRUNGS ®) Digital PCR Assays (TRUdPCR®) Product Portfolio:
Slide 10: Overview – MDx Division
Overview – MDx Division Well Established PAN-India & Comprehensive Brand Global Presence Molecular Diagnostics Only company to have Product & customer support Well established molecular qPCR Assays, Lateral Flow access available to over 600 diagnostics (MDx) brand Tests and NGS assays labs / hospita
Slide 11: Journey at a Glance
1 2 JOURNEY AT A GLANCE 3 @ @ 2011-2013 %& Founded as a @ @ 2014-2016 %& Entry into Molecular @ 2017-2018 1 & Received FMPCCI Lifesciences company Diagnostics with Launch ( =) } Outstanding Achievement %e Initiated R&D in TRUPCR’ of TRUPCR® MDx Kits in _ Award Molecular Diagnostics : Infectious Dise
Slide 12: Our Strategic Priorities
Our Strategic Priorities Market Penetration: Portfolio Expansion: We aim to boost sales with current Leveraging our R&D strengths, we customers and channel partners by continuously evolve our portfolio – with expanding the range of products within new assays in qPCR, Lateral flow their existing port
Slide 13: Growth Canvas
Sales in INR Millions Growth Canvas
Slide 14: MDx Business – Financials Highlights – 9 Months 2025-26
MDx Business – Financials Highlights – 9 Months/2025-26 9,906.39 * 5,164.58 6,361.92 ** 6,480.29 9 Months 2024-25 9 Months 2025-26 9 Months 2024-25 9 Months 2025-26 Revenue from Operations EBITDA 9 Months 2024-25 9 Months 2025-26 *** 5,105.04 6,229.18 *** 3,934.98 5,009.32 Rs. In Lakh. 9 Months 2024
Slide 15: Business Outlook – MDx (FY 2025-26 – 3B India)
Business Outlook – MDx (FY 2025-26 – 3B India) Market Overview & Growth Outlook The Total Addressable Market (TAM) for Molecular Diagnostics (MDx) in India is estimated at approx. ₹400–500 Cr. We hold a 12%–15% market share, positioning us among the market leaders. The MDx industry is projecte
Slide 16: Business Outlook – MDx (Q3/2025-26)
Business Outlook – MDx (Q3/2025-26) We closed Q3 2025-26 with INR 4,867.50* Lakh compared to INR 2,328.30 Lakh in Q3 2024-25. This includes consolidated sales from TRUPCR Europe Limited, Manchester of INR 559.77 Lakh and sales from Coris BioConcept SRL, Belgium of INR 2,400.70 Lakh. In Q3 2025-26, w
Slide 17: Business Outlook – MDx (9 Months/2025-26)
Business Outlook – MDx (9 Months/2025-26) For the 9 Months period, 3B’s standalone (MDx) growth is ~12% which is primarily affected due to flu, dengue/chikungunya sales spike of INR 380.00 Lakh in Q2 and 40 Lakh in Q3 last year. If we remove this seasonal spike, our growth would have been ~20%. Sale
Slide 18: Future Growth Strategy
Future Growth Strategy To continue our growth journey and to ward off seasonal spikes in coming years, we are putting following efforts: Marketing: Participating in multiple international events and upcoming events like the WHX Labs – Dubai (10th – 13th Feb’26). This year we are also participating
Slide 19: Sales Model – MDx (FY 2025-26 – 3B India)
Sales Model – MDx (FY 2025-26 – 3B India) The company operates through three primary sales models in India: a) Tender Sales: This accounts for approximately 5%-7% of the total sales and it depends on type of tender, etc. b) Contractual / Reagent Rental Model: In this model, we provide molecular diag
Slide 20: Our Footprints in India
Our Footprints in India Head Office & Manufacturing Site Corporate Office – Delhi Sales Office - Mumbai Sales & Marketing Team Distributor Network
Slide 21: Our Global Presence
Our Global Presence We have widespread acceptance globally with our presence now in over 70 countries spanning across Europe, Middle East, APAC, LATAM, and North America (including the United States and Canada). Now we are expanding in Africa through strategic partnerships with channel partners.
Slide 22: Business Outlook – International
Business Outlook – International Global Expansion: Appointed new channel partners to strengthen international presence. Territorial Growth: Added customers in existing and new markets across Europe, Africa, and APAC. Regulatory Progress: Completed product registrations in several countries; on
Slide 23: Exports – Past Trend & Near Term Vision
Exports – Past Trend & Near Term Vision Our exports have grown substantially, as shown by the yearly figures below. This year, we project export growth of 15-20% though, geopolitical issues across countries may effect the sales. We now have presence across 70+ countries & 200+ customers. We have add
Slide 24: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site In Q3 FY 2025-26, TRUPCR® Europe Limited (TPE) sales have gained momentum with an increase of ~14% as shown below. GBP 417,623 GBP 477,288 Q3 FY 2024-25 Q3 FY 2025-26 Although 9 Months Sales are up by ~13% as shown below, we expect TPE to grow at 15-20% for t
Slide 25: TRUPCR Europe – Events & Conferences 2025-26
TRUPCR® Europe – Events & Conferences 2025-26 TPE had participating at the world’s largest medical trade fair, MEDICA, held annually in Düsseldorf, Germany, serves as a global marketplace for medical technology, diagnostics, and digital health, attracting exhibitors and visitors from over 70 countri
Slide 26: Events & Conferences
Events & Conferences Our strong international presence is reinforced through active participation in global conferences, where we showcase our products and introduce new verticals. These events are key to engaging stakeholders, building partnerships, and expanding global awareness. Our participation
Slide 27: Events & Conferences - International
Events & Conferences - International We continue to strengthen our global outreach and brand visibility through participation in leading international diagnostic platforms, including WHX Labs 2026 in Dubai and ADLM 2026 USA. These strategic engagements provide opportunities to showcase the Company’s
Slide 28: Coris Performance Review
CORIS PERFORMANCE REVIEW • In FY’25 (Jan-Dec) Coris had sales of EUR 4.71M and an EBITDA loss of EUR 325K compared to EUR 5.22M sales and an EBITDA loss of EUR 215K in FY’24 (Jan-Dec). • Coris billed its HAT* order of EUR 810K in the last quarter (Oct-Dec) resulting in substantial increase in profit
Slide 29: Coris Performance Review
CORIS PERFORMANCE REVIEW • To make the financial year uniform with 3B, Coris’ financial year has been changed to 31st March, so for this year, Coris’ financial year will be for 15 months (Jan’25-Mar’26). • For the 12 months ended Dec’25, if we exclude the HAT order supplied of EUR 1.35M (EUR 540K in
Slide 30: EU IVDR Certification
EU IVDR Certification On track towards IVDR certification of our product portfolio • Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) was published on 5 April 2017, repealing Directive 98/79/EC and introducing a strengthened regulatory framework applicable from 26 May 2026. • 3
Slide 31: Our Certifications
Our Certifications ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India Over 120 Parameters are CE-IVD marked The company is on track to achieve IVDR compliance by mid-FY 20
Slide 32: What Sets us Apart
What Sets us Apart Largest CE-IVD and Indian IVD Product Range with over 120 PCR assays developed and commercially available Large, expansive and highly loyal customer base spread across government & private hospitals and labs in over 70 countries Well experienced, strong and well retained R&D
Slide 33: Our R&D Strengths
Our R&D Strengths Our well retained R&D team of scientific professionals including Ph.Ds. and M.Scs. brings vast experience in molecular diagnostics, assay design, and bioinformatics which reflects a stable, motivated workforce committed to scientific excellence and long-term innovation. This is
Slide 34: Comprehensive Panels for Syndromic Testing
Comprehensive Panels for Syndromic Testing The COVID-19 pandemic has underscored the importance of multiplex PCR TRUPCR® Flu Panel with RSV Detection Kit assays and syndromic diagnostic testing for infectious diseases, highlighting their utility in rapidly diagnosing and managing contagious illnesse
Slide 35: Antimicrobial Resistance – A Silent Pandemic
Antimicrobial Resistance – A Silent Pandemic Antimicrobial resistance (AMR) has become one of the most significant threats to public health worldwide, often referred to as the "silent pandemic" due to its gradual and insidious nature. Image Source: AMR Action Fund • Encouraging judicious use of anti
Slide 36: Solutions by 3B - to combat Antimicrobial Resistance
Solutions by 3B - to combat Antimicrobial Resistance We offer an extensive range of RT-PCR-based and lateral flow assays that demonstrates our proactive approach to addressing the global concern of antimicrobial resistance (AMR). TRUPCR® have both singlex and multiplexing RT-PCR assays for the detec
Slide 37: TRURAPID AMR Rapid Tests
Solutions by 3B - to combat Antimicrobial Resistance We are pleased to inform that we have successfully completed the collaborative R&D of the Rapid Tests for Anti- Microbial Resistance (AMR). The below assays have been launched to cater to the AMR segment: TRURAPID® RESIST-5 OKNVI Rapid Test (For
Slide 38: Next-Gen Sequencing (NGS) Vertical
Next-Gen Sequencing (NGS) Vertical We have started getting some traction for the TRUNGS® assays from the customers however, it is very low. The NGS market is at a very nascent stage and is divided in Whole Genome Sequencing, Whole Exome Sequencing, NIPT etc. With the TRUNGS® vertical, our main inten
Slide 39: Digital PCR
Digital PCR Our Research and Development (R&D) team is committed to the ongoing development of innovative products leveraging cutting-edge technologies. Through our dedication to scientific advancement and technological innovation, we strive to address emerging challenges and meet the evolving needs
Slide 40: Automated Extraction System
Automated Extraction System We are trying to offer automated extraction systems to our customers. Our team alongwith VGT’s team has invested considerable time and effort into identifying an automated extraction system that meets the growing needs of our customers. With this new addition, we are conf
Slide 41: Long Term Contracts
Long Term Contracts Signing long-term contracts with large customers is a strategic move that provides stability and predictability to the business operations. By securing commitments for 2-3 years, we can better forecast revenue streams and plan resources accordingly, reducing uncertainty and mitig
Slide 42: Utilization of Funds / Existing & Utilized Capacity
Utilization of Funds During the last 2 years, we have evaluated several companies in the IVD space, however, the valuations were high due to demand from diagnostic companies based on Covid profits. Also, the Sales & EBITDA were not matching our IRR or future growth possibility, hence we did not proc
Slide 43: 3B for CSR
3B for CSR Army Wives Welfare Association or AWWA for short is an association that works for the welfare of the spouses, children and dependents of Army personnel. The aim of AWWA therefore is to support and augment the official welfare efforts within the Indian Army, focusing primarily on the wel-
Slide 44: 3B for CSR
3B for CSR Sightsavers is an international organisation that works in more than 30 countries to eliminate avoidable blindness, and fight for the rights & needs of people with disability. Sightsavers’ work in India has enabled thousands of people to lead lives of independence and dignity. “3B” has be
Slide 45: 3B for CSR
3B for CSR Prerna Sewa Trust, Bhopal, has been serving poor patients at Hamidia Hospital, Bhopal for decades through daily meals, free medicines, medical equipment, and support for treatment of serious ailments. In line with our CSR commitment, 3B has been supporting the Trust by funding medical aid
Slide 46: 3B for CSR
3B for CSR Cachar Cancer Hospital & Research Centre is committed to providing affordable and accessible cancer care to patients across Northeast India, particularly serving economically disadvantaged communities. The centre has received national and international recognition for its impactful work,
Slide 47: Recognitions & Awards
Recognitions & Awards Received the “Outstanding Received the “National Received the “Outstanding Achievement Award” in MSME Award – 2018” by Achievement Award” in recognition of excellence in Hon’ble President of India on recognition of excellence in R&D through technology by 11th May 2018 under MSM
Slide 48: Jai Hind
JAI HIND 2B BlackBio Dx Ltd.
3B BlackBio Dx — Investor Presentation (February 2026) on 6ix